Soligenix closes $7.5M public offering; cash runway extended through 2026

SOLIGENIX, INC.

Gross proceeds of ~$7.5M from sale of 5,555,560 units at $1.35/unit, each consisting of one share (or pre-funded warrant) and one warrant.
Warrants exercisable at $1.35 per share for five years from issuance; 1,162,064 existing warrants amended to same terms.
Cash runway now extends through end of 2026 to fund key clinical/commercial inflection points.
Net proceeds to fund R&D, commercialization, working capital and general corporate purposes.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.